IntelGenx, RedHill, Juste deal

IntelGenx and Redhill granted Juste exclusive rights to commercialize migraine drug Rizaport rizatriptan in Spain and a right of first refusal in Belize, the Caribbean, Chile, Colombia, Costa Rica, the Dominican Republic, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, the Middle East and Morocco. RedHill has exclusive, worldwide rights to co-develop and commercialize Rizaport from IntelGenx. ...